BioPharma Dive1d
GLP-1 drug compounding is in limbo. Will the FDA draw out its decision?
The agency is due to make a determination on the shortage status of Zepbound by Dec. 19. But another delay could be possible ...
This GLP-1 drug maker is skipping the hard sell to focus on access and safety
Lilly’s work discouraging cosmetic use of weight-loss drugs helped make it a 2024 Brands That Matter honoree. Use of GLP-1 ...
Weight loss costs: Iowans struggle with insurance and access to ozempic, other GLP-1 drugs
Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...
Medscape6h
Diabetes Drugs and Eye Disease: These Protect, These Don’t
Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...
The Lancet18h
The era of GLP-1 receptor agonists: costs versus benefits
Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...
FoodNavigator1d
Could GLP-1 drugs curb alcohol consumption?
Now, research from Henry Ford Health, has found that weight-loss drugs, including GLP-1, could also impact alcohol ...
Psychology Today2d
Can GLP-1 Agonists Treat Alcoholism?
GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...
GLP-1 drugs linked to lower risk for dementia in older adults with diabetes: Study
A new study found that adults over the age of 60 and on a GLP-1 medication reduced their likelihood of developing dementia by ...